Answers are grounded in this paper and cite their sources.
Background: Modified induction chemotherapy may be considered in acute myeloid leukemia (AML) when treatment tolerance and toxicity are important clinical concerns. This study evaluated one-year clinical outcomes in patients with non-acute promyelocytic leukemia (non-APL) AML treated with modified 2+5 induction chemotherapy. Materials and Methods: This prospective observational cohort study enrolled 38 consecutive patients with non-APL AML who received modified 2+5 induction chemotherapy at Kidwai Memorial Institute of Oncology, Bengaluru, India, with one-year follow-up. The primary outcome was one-year overall survival (OS). Secondary outcomes were complete remission (CR), one-year progression-free survival (PFS), induction mortality, and treatment-related complications. OS and PFS were summarized using the Kaplan-Meier method; exploratory associations were assessed using the chi-square or Fisher's exact test. Results: CR was achieved in 27 patients (71.1%); 5 (13.2%) had refractory disease, and 6 (15.8%) died during induction before marrow assessment. At one year, 21 patients (55.3%) were alive and 16 (42.1%) were alive without a documented PFS event. Febrile neutropenia was the most common complication (89.5%), followed by culture-positive infection (57.9%) and intensive care unit admission (55.3%). Post-induction remission status was associated with one-year survival and PFS status; as a post-treatment variable unavailable in early deaths, it was not interpreted as a baseline prognostic factor. Conclusion: Modified 2+5 induction chemotherapy resulted in a CR rate of 71.1%; 55.3% of patients were alive at one year and 42.1% were alive without a documented PFS event. Given the small, single-center cohort and absence of a comparator arm, these findings should be considered exploratory.
No takes yet. Share an insight, caveat, or question.
A.H. et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: